CN1329392C - 取代的吡唑 - Google Patents

取代的吡唑 Download PDF

Info

Publication number
CN1329392C
CN1329392C CNB018170692A CN01817069A CN1329392C CN 1329392 C CN1329392 C CN 1329392C CN B018170692 A CNB018170692 A CN B018170692A CN 01817069 A CN01817069 A CN 01817069A CN 1329392 C CN1329392 C CN 1329392C
Authority
CN
China
Prior art keywords
phenyl
group
piperazine
tetrahydrochysene
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018170692A
Other languages
English (en)
Chinese (zh)
Other versions
CN1468239A (zh
Inventor
J·G·布雷藤布彻尔
H·蔡
J·P·爱德华兹
C·A·格里斯
D·J·古斯丁
H·哈图亚
S·P·梅杜纳
B·A·皮奥
K·L·泰斯
J·韦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
3 Dimensional Pharmaceuticals Inc
Original Assignee
3 Dimensional Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3 Dimensional Pharmaceuticals Inc filed Critical 3 Dimensional Pharmaceuticals Inc
Publication of CN1468239A publication Critical patent/CN1468239A/zh
Application granted granted Critical
Publication of CN1329392C publication Critical patent/CN1329392C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
CNB018170692A 2000-08-14 2001-08-10 取代的吡唑 Expired - Lifetime CN1329392C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22513800P 2000-08-14 2000-08-14
US60/225,138 2000-08-14
US09/928,122 2001-08-10
US09/928,122 US7309703B2 (en) 2000-08-14 2001-08-10 Substituted pyrazoles

Publications (2)

Publication Number Publication Date
CN1468239A CN1468239A (zh) 2004-01-14
CN1329392C true CN1329392C (zh) 2007-08-01

Family

ID=26919335

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018170692A Expired - Lifetime CN1329392C (zh) 2000-08-14 2001-08-10 取代的吡唑

Country Status (17)

Country Link
US (9) US7589202B2 (US07772236-20100810-C00042.png)
EP (1) EP1309591B1 (US07772236-20100810-C00042.png)
JP (1) JP5140225B2 (US07772236-20100810-C00042.png)
CN (1) CN1329392C (US07772236-20100810-C00042.png)
AR (1) AR035714A1 (US07772236-20100810-C00042.png)
AT (1) ATE352552T1 (US07772236-20100810-C00042.png)
AU (2) AU2001281255B2 (US07772236-20100810-C00042.png)
CA (1) CA2419540A1 (US07772236-20100810-C00042.png)
CY (1) CY1106032T1 (US07772236-20100810-C00042.png)
DE (1) DE60126286T2 (US07772236-20100810-C00042.png)
DK (1) DK1309591T3 (US07772236-20100810-C00042.png)
ES (1) ES2281434T3 (US07772236-20100810-C00042.png)
HK (1) HK1052509B (US07772236-20100810-C00042.png)
MX (1) MXPA03001421A (US07772236-20100810-C00042.png)
NZ (1) NZ524193A (US07772236-20100810-C00042.png)
PT (1) PT1309591E (US07772236-20100810-C00042.png)
WO (1) WO2002014314A2 (US07772236-20100810-C00042.png)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
ES2281434T3 (es) * 2000-08-14 2007-10-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
US7332494B2 (en) * 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
WO2002051983A2 (en) * 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
US20040147503A1 (en) * 2002-06-04 2004-07-29 Sheila Zipfeil Novel compounds and compositions as cathepsin inhibitors
US20030073672A1 (en) * 2001-09-05 2003-04-17 Breitenbucher J. Guy Method for treating allergies using substituted pyrazoles
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
CN1867336B (zh) * 2002-06-12 2010-05-12 凯莫森特里克斯股份有限公司 1-芳基-4-取代的哌嗪衍生物及其制药用途
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
GB0220214D0 (en) * 2002-08-30 2002-10-09 Novo Pharmaceuticals De Ltd Compounds and their use
PL375053A1 (en) 2002-09-24 2005-11-14 Novartis Ag Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
US7384970B2 (en) 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US7109243B2 (en) 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7173051B2 (en) 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
EA200801812A1 (ru) 2003-09-17 2009-06-30 Янссен Фармацевтика Н.В. Сопряженные гетероциклические соединения
EP1715921B1 (en) * 2003-09-25 2013-04-24 Abraxis BioScience, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
AU2005219438B2 (en) * 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7745491B2 (en) * 2004-08-12 2010-06-29 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20080207683A1 (en) * 2007-02-15 2008-08-28 Darin Allen Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080200454A1 (en) * 2007-02-15 2008-08-21 Ameriks Michael K Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080269241A1 (en) * 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090118274A1 (en) * 2007-02-15 2009-05-07 Darin Allen Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090099157A1 (en) * 2007-02-15 2009-04-16 Ameriks Michael K Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
US20100046516A1 (en) * 2007-06-26 2010-02-25 Media Patents, S.L. Methods and Devices for Managing Multicast Traffic
EP2276198B1 (en) * 2007-06-26 2012-01-18 Media Patents, S. L. Device for managing multicast groups
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
WO2009102937A1 (en) * 2008-02-14 2009-08-20 Sunesis Pharmaceuticals, Inc. Processes for the preparation of carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
EP3011958A1 (en) 2008-06-20 2016-04-27 Novartis AG Paediatric compositions for treating multiple sclerosis
US8829011B2 (en) 2008-10-29 2014-09-09 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
CA2740195A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
SI2628481T1 (sl) 2009-06-11 2016-08-31 Abb Vie Bahamas Limited Trisubstituirani heterocikli kot inhibitorji replikacije HCV virusa hepatitisa C
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US9527845B2 (en) 2014-12-30 2016-12-27 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
EP3377060B1 (en) 2015-11-20 2020-08-19 Lundbeck La Jolla Research Center, Inc. Pyrazole derivatives, processes for their preparation and uses thereof
WO2017087863A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
US10583137B2 (en) 2015-12-02 2020-03-10 The Scripps Research Institute Triazole DAGLα inhibitors
TW201806956A (zh) 2016-06-29 2018-03-01 諾維拉治療公司 二氮呯酮衍生物及治療ｂ型肝炎感染之方法
CA3029566A1 (en) 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis b infections
EP3630744B1 (en) 2017-05-23 2023-01-25 H. Lundbeck A/S Pyrazole magl inhibitors
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
EP3884948A1 (en) * 2020-03-26 2021-09-29 Ecole Polytechnique Fédérale de Lausanne (EPFL) Cathepsin inhibitors and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5016470A (US07772236-20100810-C00042.png) * 1973-06-11 1975-02-21
JPS5214765A (en) * 1975-07-25 1977-02-03 Chugai Pharmaceut Co Ltd Preparation of indazole derivatives
GB1489280A (en) * 1974-01-31 1977-10-19 Chugai Pharmaceutical Co Ltd Indazole derivatives
US4808620A (en) * 1986-07-22 1989-02-28 Yoshitomi Pharmaceutical Industries, Ltd. Pyrazolopyridine compounds, their preparation and use as platelet aggregation inhibitors
WO1998056785A1 (fr) * 1997-06-12 1998-12-17 Sumitomo Pharmaceuticals Co., Ltd. Derives de pyrazole

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914340A (en) * 1970-06-02 1975-10-21 Gen Tire & Rubber Co Block copolymerization with azoamidino compounds as initiator
JPS5640714B2 (US07772236-20100810-C00042.png) * 1974-03-04 1981-09-22
JPS5944312B2 (ja) * 1974-11-22 1984-10-29 中外製薬株式会社 インダゾ−ル誘導体の製法
US4523928A (en) * 1980-04-28 1985-06-18 Battelle Development Corporation Gasohol production from thermochemical conversion of biomass to ethanol
US4401823A (en) * 1981-05-18 1983-08-30 Uop Inc. Hydrogenolysis of polyhydroxylated compounds
US4364745A (en) * 1981-06-26 1982-12-21 Standard Oil Company (Indiana) Plant hydrocarbon recovery process
DE3132915A1 (de) * 1981-08-20 1983-03-03 Kali-Chemie Pharma Gmbh, 3000 Hannover 1,5-diphenylpyrazolin-3-on-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DK27383A (da) * 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
US4925540A (en) * 1988-10-04 1990-05-15 Delphi Research Inc. Method for treating organic waste material and an oxidation catalyst/cocatalyst composition useful therefor
FR2642759B1 (fr) 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
US5177169A (en) * 1989-04-03 1993-01-05 Colorado State University Research Foundation Method for recovering and using lignin in adhesive resins
FR2673628B1 (fr) 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
US5186722A (en) * 1991-06-25 1993-02-16 Cantrell Research, Incorporated Hydrocarbon-based fuels from biomass
JP2818061B2 (ja) * 1991-12-10 1998-10-30 三菱電機株式会社 放電加工装置
US5264576A (en) 1992-10-22 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Pyrazolo[4,3-c]pyridines which are intermediates
US5599815A (en) 1993-02-04 1997-02-04 Meiji Seika Kabushiki Kaisha Antipsychotic benzoisothiazolyl piperazine derivatives
FR2712808B1 (fr) 1993-11-25 1996-02-16 Esteve Labor Dr Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique .
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
US5516960A (en) * 1994-08-02 1996-05-14 Board Of Regents, The University Of Texas System Process for producing hydrocarbon fuels
US5776718A (en) 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
PL322409A1 (en) 1995-03-24 1998-01-19 Arris Pharm Corp Reversible protease inhibitors
TW438591B (en) 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
WO1996041633A1 (en) 1995-06-08 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
FR2742052B1 (fr) 1995-12-12 1998-04-10 Esteve Labor Dr Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
DE19602505A1 (de) 1996-01-25 1997-07-31 Merck Patent Gmbh 1-(Pyrazol-4-Indol-3-yl)-Piperidine
DK0912601T4 (da) 1996-04-22 2009-03-09 Massachusetts Inst Technology Suppression af immunrespons ved inhibering af cathepsin S
TW575583B (en) 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
US5830850A (en) * 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
GB9626643D0 (en) * 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
FR2767827A1 (fr) 1997-09-03 1999-02-26 Adir Nouveaux derives de l'indole et de l'indazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PL202226B1 (pl) 1997-11-05 2009-06-30 Novartis Ag Nitryl dipeptydowy, jego zastosowanie lecznicze i zawierająca go kompozycja farmaceutyczna
GB9806287D0 (en) 1998-03-24 1998-05-20 Synphar Lab Inc Monobactam enzyme inhibitors
WO1999058153A1 (en) 1998-05-08 1999-11-18 Brigham & Women's Hospital Methods of diagnosing and modulating autoimmunity
AU2560000A (en) 1999-02-20 2000-09-04 Astrazeneca Ab Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin
EP1159273A1 (en) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
JP2003506364A (ja) 1999-07-30 2003-02-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼインヒビターとして有益な新規スクシネート誘導体化合物
AU7490900A (en) 1999-09-16 2001-04-17 Axys Pharmaceuticals, Inc. Chemical compounds and compositions and their use as cathepsin s inhibitors
AU1650501A (en) 1999-12-03 2001-06-12 Ono Pharmaceutical Co. Ltd. 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
US6214813B1 (en) * 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
AU8645401A (en) * 2000-08-14 2002-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
ES2281434T3 (es) * 2000-08-14 2007-10-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
US7332494B2 (en) * 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
EP1184443A1 (en) * 2000-09-04 2002-03-06 Biofuel B.V. Process for the production of liquid fuels from biomass
PT1315491E (pt) * 2000-09-06 2006-10-31 Ortho Mcneil Pharm Inc Utilizacao de pirazoles substituidos para o fabrico de um medicamento para o tratamento de alergias

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5016470A (US07772236-20100810-C00042.png) * 1973-06-11 1975-02-21
GB1489280A (en) * 1974-01-31 1977-10-19 Chugai Pharmaceutical Co Ltd Indazole derivatives
JPS5214765A (en) * 1975-07-25 1977-02-03 Chugai Pharmaceut Co Ltd Preparation of indazole derivatives
US4808620A (en) * 1986-07-22 1989-02-28 Yoshitomi Pharmaceutical Industries, Ltd. Pyrazolopyridine compounds, their preparation and use as platelet aggregation inhibitors
WO1998056785A1 (fr) * 1997-06-12 1998-12-17 Sumitomo Pharmaceuticals Co., Ltd. Derives de pyrazole

Also Published As

Publication number Publication date
WO2002014314A2 (en) 2002-02-21
NZ524193A (en) 2004-12-24
US7452890B2 (en) 2008-11-18
US20070004738A1 (en) 2007-01-04
US7393850B2 (en) 2008-07-01
WO2002014314A3 (en) 2002-06-06
CA2419540A1 (en) 2002-02-21
ES2281434T3 (es) 2007-10-01
HK1052509B (zh) 2007-09-07
CN1468239A (zh) 2004-01-14
ATE352552T1 (de) 2007-02-15
US20070004755A1 (en) 2007-01-04
DE60126286T2 (de) 2007-11-15
DK1309591T3 (da) 2007-03-26
US7388011B2 (en) 2008-06-17
US7417046B2 (en) 2008-08-26
MXPA03001421A (es) 2004-01-26
US7429591B2 (en) 2008-09-30
AU8125501A (en) 2002-02-25
US20080300255A1 (en) 2008-12-04
PT1309591E (pt) 2007-04-30
EP1309591B1 (en) 2007-01-24
JP2004512272A (ja) 2004-04-22
EP1309591A2 (en) 2003-05-14
US20070004754A1 (en) 2007-01-04
US7772236B2 (en) 2010-08-10
US20070004747A1 (en) 2007-01-04
AR035714A1 (es) 2004-07-07
US20020040020A1 (en) 2002-04-04
US20070021437A1 (en) 2007-01-25
HK1052509A1 (en) 2003-09-19
US20070010530A1 (en) 2007-01-11
US7309703B2 (en) 2007-12-18
DE60126286D1 (de) 2007-03-15
JP5140225B2 (ja) 2013-02-06
US20080293732A1 (en) 2008-11-27
CY1106032T1 (el) 2011-04-06
AU2001281255B2 (en) 2006-07-20
US7589202B2 (en) 2009-09-15

Similar Documents

Publication Publication Date Title
CN1329392C (zh) 取代的吡唑
CN105377846B (zh) 有机化合物
CN101952283B (zh) 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
ES2392570T3 (es) Derivados de quinoxalina como inhibidores de la actividad de tirosina quinasa de quinasas Janus.
ES2295826T3 (es) Derivados de bencimidazol e imidazo-piridina que tienen afinidad por los receptores de las melanocortinas y su utilizacion como medicamentos.
TWI816809B (zh) 黑皮質素亞型-2受體(mc2r)拮抗劑及其用途
CN105814050A (zh) 用作tnf活性调节剂的吡唑并吡啶衍生物
CN102791697A (zh) 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物
KR20050099531A (ko) 카나비노이드 수용체 리간드로서의피라졸로[1,5-ａ][1,3,5]트리아진 유도체
CN102164604A (zh) 用作激酶调节剂的稠合杂环化合物
CN101730699A (zh) 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
CN102695708A (zh) N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
CN101362764A (zh) 具有PDE-5抑制活性的5,7-二氨基吡唑并[4,3-d]嘧啶
CN110141570A (zh) 药物化合物
CN101084199A (zh) 取代的氨基化合物及其用途
CN102695710A (zh) 三环吡唑胺衍生物
CN101821279A (zh) 某些化学个体、组合物和方法
CN102812029A (zh) 吡咯并吡嗪衍生物及其作为jak和syk抑制剂的用途
CN101421250A (zh) 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物
JP2007532526A (ja) ピラゾロ［４，３−ｄ］ピリミジン類
BRPI0918517B1 (pt) composto, composição farmacêutica, e, uso de um composto
CN101641329A (zh) 具有5-ht6受体亲和力的6＇取代的吲哚和吲唑衍生物
CN104059054B (zh) 用于治疗癌症的三级环状胺alk激酶抑制剂
BR112020026337A2 (pt) Compostos tricíclicos
TW407155B (en) Novel piperazine derivatives having GPIIb/IIIa antagonistic activity and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070801